[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Controversies in Neurology
September 2001

Triptans Are All Different

Author Affiliations

From The New England Center for Headache, Stamford, Conn, and the Department of Neurology, Yale University School of Medicine, New Haven, Conn.

 

JOHN N.WHITAKERMD

Arch Neurol. 2001;58(9):1479-1480. doi:10.1001/archneur.58.9.1479

THERE ARE 4 triptans currently available in the United States, and 3 more are expected to be approved by the Food and Drug Administration. Although they are all 5-HT1B/1D(serotonin1B/1D) agonists, they each have slightly different pharmacokinetic characteristics and clinical strengths and weaknesses, and they can be used in special ways to optimize migraine therapy. Thus, triptans differ significantly clinically, and the astute clinician uses these differences to optimize patient treatment.1,2

First Page Preview View Large
First page PDF preview
First page PDF preview
×